You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Heparin Sodium 5,000 Units In Dextrose 5% In Plastic Container, and when can generic versions of Heparin Sodium 5,000 Units In Dextrose 5% In Plastic Container launch?

Heparin Sodium 5,000 Units In Dextrose 5% In Plastic Container is a drug marketed by Mcgaw and is included in one NDA.

The generic ingredient in HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER is heparin sodium. There are seventy-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Heparin Sodium 5,000 Units In Dextrose 5% In Plastic Container

A generic version of HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as heparin sodium by HOSPIRA on April 28th, 1983.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER?
  • What are the global sales for HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER?
  • What is Average Wholesale Price for HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER?
Summary for HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Drug patent expirations by year for HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Recent Clinical Trials for HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vaneltix Pharma, Inc.Phase 2
Prevail Infoworks, IncPhase 2
The First Affiliated Hospital with Nanjing Medical UniversityN/A

See all HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mcgaw HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER heparin sodium INJECTABLE;INJECTION 019130-002 Dec 31, 1984 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Heparin Sodium in 5% Dextrose Injection

Introduction

Heparin Sodium in 5% Dextrose Injection is a critical anticoagulant used in various medical procedures, including the prevention and treatment of venous thrombosis, pulmonary embolism, and other thrombotic conditions. Here, we delve into the market dynamics and financial trajectory of this drug.

Market Size and Growth

The global heparin market, which includes Heparin Sodium in 5% Dextrose Injection, was valued at USD 7.42 billion in 2022. It is projected to reach USD 10.93 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 5.05% during the forecast period of 2023 to 2030[2].

Drivers of Market Growth

Several factors are driving the growth of the heparin market:

Increasing Prevalence of Cardiovascular Diseases

Cardiovascular diseases are a leading cause of death globally, with over 800,000 individuals in the United States dying each year from stroke and other cardiovascular disorders. This increasing prevalence is a significant driver for the demand of anticoagulants like heparin[2].

Rising Number of Surgical Procedures

The growing number of accidents and medical surgeries contributes to the increased demand for heparin. This is particularly true for procedures that require anticoagulation to prevent thrombotic events[2].

Improving Healthcare Infrastructure

Increased healthcare expenditure and efforts to improve healthcare infrastructure are boosting the market. Public and private initiatives to enhance healthcare facilities and raise patient awareness also contribute to the market's growth[2].

Geriatric Population and Thrombotic Events

The rising geriatric population and the surge in thrombotic events are additional factors driving the market's growth. Older patients often require anticoagulant therapy, which increases the demand for heparin products[2].

Restraints and Challenges

Despite the growth drivers, there are several challenges facing the heparin market:

High Cost and Side Effects

The high cost associated with heparin drugs and the potential side effects, such as bleeding and thrombocytopenia, can deter patients and healthcare providers. These factors can impede market growth[2].

Stringent Regulatory Framework

Strict governmental regulations on the approval process for heparin products can slow down market growth. Ensuring compliance with these regulations adds to the complexity and cost of bringing new products to market[2].

Competition and Counterfeit Drugs

The rise in competition among market players and the presence of counterfeit drugs can also pose significant challenges to the legitimate heparin market[2].

Market Segmentation

The global heparin market is segmented based on several criteria:

Product Type

The market includes unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). Each type has different applications and market shares[2].

Mode of Administration

Heparin can be administered orally or parenterally. Parenteral administration, which includes intravenous and subcutaneous routes, is more common for Heparin Sodium in 5% Dextrose Injection[2].

Source

Heparin can be derived from bovine or porcine sources. Porcine-derived heparin, like Heparin Sodium in 5% Dextrose Injection, is widely used due to its efficacy and safety profile[1][5].

Therapeutic Applications

Heparin is used in various therapeutic areas, including cardiovascular, respiratory, oncology, and nephrology. Its use in pre-surgical, post-surgical, and diagnostic procedures is also significant[2].

End User Segment

Hospitals dominate the end-user segment of the global heparin market due to the high demand for anticoagulant therapy in these settings. The need for continuous intravenous infusion of heparin in hospital settings drives this demand[2].

Regional Analysis

The global heparin market is analyzed across various regions, with each region showing different market dynamics based on healthcare infrastructure, patient population, and regulatory environments. Emerging economies offer significant growth opportunities due to increasing healthcare investments and rising patient awareness[2].

Financial Trajectory

The financial trajectory of Heparin Sodium in 5% Dextrose Injection is closely tied to the overall heparin market. Here are some key financial insights:

Revenue Growth

The market is expected to grow from USD 7.42 billion in 2022 to USD 10.93 billion by 2030, indicating a steady revenue increase driven by increasing demand and expanding applications[2].

Investment in Research and Development

Continuous investment in research and development is crucial for the growth of the heparin market. Innovations in product formulations, delivery methods, and safety profiles are expected to drive market expansion[2].

Market Opportunities

Emerging markets and the rise in reagent rental businesses offer profitable opportunities for market players. The increasing number of clinical trials and product innovations will further propel market growth[2].

Key Takeaways

  • The global heparin market, including Heparin Sodium in 5% Dextrose Injection, is projected to grow significantly due to increasing demand driven by cardiovascular diseases and surgical procedures.
  • The market faces challenges such as high costs, side effects, and stringent regulatory frameworks.
  • Hospitals are the primary end-users, and emerging economies offer significant growth opportunities.
  • Continuous investment in research and development is essential for market growth.

FAQs

Q: What is the primary use of Heparin Sodium in 5% Dextrose Injection? A: Heparin Sodium in 5% Dextrose Injection is primarily used for anticoagulant therapy, including the prevention and treatment of venous thrombosis, pulmonary embolism, and other thrombotic conditions[1][5].

Q: What are the main drivers of the heparin market growth? A: The main drivers include the increasing prevalence of cardiovascular diseases, rising number of surgical procedures, improving healthcare infrastructure, and the growing geriatric population[2].

Q: What are the challenges facing the heparin market? A: Challenges include high costs, potential side effects, stringent regulatory frameworks, competition, and the presence of counterfeit drugs[2].

Q: Which segment dominates the end-user market for heparin? A: Hospitals dominate the end-user segment due to the high demand for anticoagulant therapy in these settings[2].

Q: What is the projected market size of the global heparin market by 2030? A: The global heparin market is expected to reach USD 10.93 billion by 2030, growing at a CAGR of 5.05% during the forecast period[2].

Cited Sources

  1. Heparin Sodium in 5% Dextrose Injection - FDA Label[1]
  2. Global Heparin Market - Data Bridge Market Research[2]
  3. Effect of pH on the stability of heparin in 5% dextrose solutions - Academic.oup.com[3]
  4. Heparin Sodium in 5% Dextrose Injection - FDA Label[4]
  5. CIV Heparin Sodium in 5% Dextrose Injection - Health Canada[5]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.